Features

Agencies How Adept Pharma tackled the opioid crisis head on

How Adept Pharma tackled the opioid crisis head on

The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.

Commercial PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

As with most drug pricing battles, patients yet again are caught in the crossfire.

Features The MM&M buyer's guide to boutique consulting services

The MM&M buyer's guide to boutique consulting services

You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.

Features Read the April 2018 Digital Edition

Read the April 2018 Digital Edition

Read the April 2018 issue in its entirety.

Pipeline High-profile candidates challenge marketers well in advance of launch

High-profile candidates challenge marketers well in advance of launch

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.

Commercial Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Commercial Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

Features Read the March 2018 Digital Edition

Read the March 2018 Digital Edition

Read the March 2018 issue in its entirety.

Campaigns DTC ads 2017: The good, the bad, and the ugly

DTC ads 2017: The good, the bad, and the ugly

We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.

Campaigns DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

DTC Report 2018: Will more supersized campaigns follow Opdivo's and Keytruda's massive strikes?

Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?